British-Swedish pharmaceutical giant AstraZeneca will withdraw its coronavirus vaccine from markets around the world.
AstraZeneca’s decision comes after the company admitted the shot could cause deadly blood clots and faced a class-action lawsuit brought by apparent victims and families of deceased victims. However, AstraZeneca said the withdrawal was due to commercial considerations.
background
The Oxford-AstraZeneca COVID-19 vaccine was a viral vector vaccine developed in collaboration with the University of Oxford and manufactured by the University for various companies. Serum Institute of India. It relied on a modified version of the Chimpanzee His adenovirus and was sold under various brand names such as Vaxzevria and His Covishield.
Blaze News previously reported that the shooting approved It began use in the UK in December 2020 and was subsequently approved by the World Health Organization. Although it has never been approved for deployment in the United States, the Biden administration has agreed to share up to 60 million doses with other countries.
Within one year of approval, the vaccine will injected Over 2.5 billion times worldwide.
It wasn’t just the vaccine. was popular British Prime Minister Boris Johnson at the time called it a “victory for British science”. passed off “Safe and effective” mainstream media and various so-called experts upon both sides of the Atlantic Ocean.
Some unfortunate members of the British public, and others around the world who were similarly advised to get vaccinated, were soon to learn firsthand that the so-called experts were completely wrong.
Doctors began noticing in 2021 that healthy people were seriously injured or dying after receiving the Astazeneca shot. Faced with mounting evidence linking the vaccine to harmful side effects, various countries temporarily pulled the vaccine from the market due to reports of abnormal bleeding, thrombocytopenia, blood clots and sudden death.
German and Scandinavian researchers Decided Some vaccine recipients developed a clotting disorder called vaccine-induced immune thrombotic thrombocytopenia, in which antibodies are produced that activate platelets and cause blood clots. The researchers suggested that there was a 1 in 100,000 chance that the vaccine would harm recipients, which is lower than the chance that the vaccine would actually keep coronavirus patients under 30 out of the hospital. expensive.
telegraph paper report Of the hundreds of suspected thromboembolic events recorded among AstraZeneca patients in the UK, at least seven were ultimately fatal for patients aged 18 to 29. Ten of the victims, aged between 30 and 39, died. Seventeen of the victims, aged between 40 and 49, died. Twenty-one of the victims, aged between 50 and 59, died. Eleven of the victims, aged between 60 and 69, died. Seven of the victims, aged between 70 and 79, died. and four were fatal for people over 80 years old.
Legal action and confession
Jamie Scott, a father of two who suffered permanent blood clot-related brain damage after receiving the AstraZeneca vaccine in April 2021, sued the company last year. His efforts to hold Big Pharma accountable have sparked an avalanche of similar complaints.
In the months since then, more than 50 other alleged vaccine victims have joined a class action lawsuit against the company.
telegraph paper report The company said it told Scott’s lawyer last year that “such a thing is unacceptable.” [thrombosis with thrombocytopenia syndrome] It is caused by generic level vaccines. ”
However, AstraZeneca acknowledged in court documents in February that “it is recognized that the AZ vaccine can cause TTS in very rare cases. A causal relationship is unknown.”
According to the International Council of Healthcare Organizations, a “very rare” side effect is one that occurs in fewer than 1 in 10,000 cases. report Independent.
The admission was a big deal, given that the company has repeatedly denied any causal link over the years.
For example, in a statement on March 14, 2021, AstraZeneca claimed Careful review showed “no evidence of increased risk of pulmonary embolism, deep vein thrombosis (DVT), or thrombocytopenia”, within defined age groups, genders, groups, or specific countries. ”
Withdrawal
According to the Telegraph, AstraZeneca voluntarily withdrew its marketing authorization in the European Union on March 5, just weeks after filing court documents containing the admission of blood clots. The withdrawal application became effective on Tuesday.
“This decision to withdraw the marketing authorization and end the use of the AstraZeneca vaccine in the EU is welcomed,” said a lawyer for alleged vaccine victims who are currently filing a class action lawsuit against the company. Deaf,” he said.
A company that started over $12 billion in product sales Other markets around the world where the company’s vaccine has been approved are expected to follow in the first quarter of 2024.
The reason for the cancellation is that there was a surplus of vaccine from other “latest vaccines.”
AstraZeneca reportedly said in a statement: “We are extremely proud of the role Vaxebria has played in ending the global pandemic. Independent estimates suggest that more than 6.5 million lives were saved in the first year of use alone. “We have delivered more than 3 billion doses worldwide.” ”
“Our efforts have been recognized by governments around the world and are widely considered a critical component to ending the global pandemic,” the statement continued. “Several mutant coronavirus vaccines have since been developed, resulting in a surplus of the latest available vaccines. This has reduced demand for Vaxebria, and it is now no longer manufactured or supplied. AstraZeneca has therefore taken the decision to begin withdrawing the marketing authorization for Vaxzebria within Europe. ”
“We will now work with regulators and partners to close this chapter and set a clear path forward for making a significant contribution to the fight against the COVID-19 pandemic,” the company added.
Sarah Moore, a partner at the law firm representing the class action, told the Telegraph: “This decision to revoke marketing authorization for those of us who have suffered bereavement or serious injury as a result of the AstraZeneca vaccine. will end,” he said. The use of the AstraZeneca vaccine in the EU will be welcomed. ”
Moore added that the reversal comes after AstraZeneca’s recent admission that its vaccine can cause TTS and that regulators around the world have paused or halted use of the vaccine following concerns about TTS. “A decision related to the fact that
Do you like Blaze News? Avoid censorship and sign up for our newsletter to get articles like this delivered straight to your inbox. Please register here!
